维普中文期刊产品整合服务

Clinical characteristics and outcomes of Chinese patients with KRAS-mutant non-small cell lung cancer after chemotherapy

查看全文 作　　者：Yawen [1,2]Zheng;Qinghua [1]Lai;Hanxi [2]Zhao;Xiaolin [2]Li;Xiaorong [2]Sun;Ligang [2]Xing 高影响力作者 机构地区：[1]Department of Oncology,Jinan Central Hospital,Cheeloo College of Medicine,Shandong University,Central hospital affiliated to Shandong First Medical University,Jinan,Shandong 250013,P.R.China;[2]Department of Radiation Oncology,Shandong Key Laboratory of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan,Shandong 250117,P.R.China高影响力机构 出　　处：《Cancer Communications》索引2021年第41卷第11期,共5页高影响力期刊 基　　金：This study was conducted in accordance with the ethical standards of the Declaration of Helsinki and approved by Shandong Cancer Hospital Shandong Cancer Hospital and Institute(No.SDTHEC2020010012)。 摘　　要：Dear Editor,The RAS gene is one of the most frequent oncogenes in human cancers,with significantly different mutation frequencies.The RAS family contains three isoforms:KRAS,HRAS and NRAS,with the KRAS mutations being more common than the other two.The KRAS mutation rate varies in non-small cell lung cancer(NSCLC)patients of different races:27%in Caucasians[1]and approximately 10%in Asians[2,3].Recently,the U.S.Food and Drug Administration(FDA)approved sotorasib(AMG510)and adagrasib(MRTX849)for the treatment of metastatic NSCLC harboring KRAS G12C mutations.In the face of novel treatment choices for KRAS-mutated NSCLC,it is indispensable to learn more about the systemic treatment of these patients.Clinical studies have shown that Caucasian patients with KRAS-mutated NSCLC had poor outcomes following first-line chemotherapy[4,5].However,studies on treatment outcomes of Asian patients with KRAS-mutated NSCLC are lacking.As the overwhelming majority of cases are diagnosed with lung adenocarcinoma,the standard first-line treatment for metastatic disease is pemetrexed-based doublet chemotherapy in combination with bevacizumab and/or immunotherapy in China.Herein,we investigated the clinical characteristics of KRAS mutation subtypes,co-occurring genomic alterations,and efficacy of first-line pemetrexed-platinum chemotherapy in Chinese KRAS-mutated NSCLC patients. 关 键 词：KRAS PATIENTS CHEMOTHERAPY
相关文献

参考文献(10)

引证文献(6)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费